Overview of London trial of intramuscular interferon-β1a in primary-progressive multiple sclerosis

Miller, David H.; Leary, Siobhan M.; Thompson, Alan J.
June 2004
Multiple Sclerosis (13524585);Jun2004 Supplement, Vol. 10, p56
Academic Journal
This short monograph describes the rationale, design and outcome of a pilot study of beta interferon in patients with primary progressive MS. A total of 50 patients were studied for 2 years using a randomized, double-blinded, placebo-controlled design. There was an emphasis on using MRI measures to evaluate outcome. The study showed that with the numbers studied, useful data could be obtained on safety and on efficacy on certain MRI measures. A larger study would be required to evaluate treatment on disability in this patient cohort and further work is needed to elucidate the relationship between quantitative MR and clinical measures over the longer term.


Related Articles

  • Glatiramer effective in delaying clinical MS.  // Formulary;Jun2008, Vol. 43 Issue 6, p220 

    The article reports on the findings of the study called PRECISE, a randomized trial of patients presented with a single clinical episode and a magnetic resonance imaging (MRI) scan suggestive of multiple sclerosis (MS). This study found that glatiramer provides a new option for delaying...

  • Overview of European pilot study of interferon β-1b in primary progressive multiple sclerosis. Montalban, Xavier // Multiple Sclerosis (13524585);Jun2004 Supplement, Vol. 10, p62 

    This short monograph describes a trial of interferon β-1b in patients with primary progressive multiple sclerosis (PPMS) or transitional MS. Designed as a randomized, placebo-controlled pilot, the trial randomly placed 73 eligible patients into two groups, placebo or interferon β-1b 8 MIU...

  • The search for a balance between short and long-term treatment outcomes in multiple sclerosis. Baumhackl, Ulf // Journal of Neurology;Jan2008 Supplement 1, Vol. 255, p75 

    Multiple sclerosis is a lifelong, immune-mediated progressive disorder. The early age of onset and the chronic nature of the disease with accumulation of physical disability, demand a long-term (“lifelong”) management, including disease-modifying immunomodulatory therapies and...

  • Methodology of clinical trials in multiple sclerosis. Mitsikostas, D. D. // Neurological Sciences;Sep2006 Supplement 5, Vol. 27, ps362 

    The scope of the paper is to summarise key issues in methodology used in clinical trials on multiple sclerosis (MS) treatment and help clinicians to better understand articles reporting the results of these trials. Relapsing ratio and disability progression based on the Expanded Disability...

  • Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Boneschi, Filippo Martinelli; Rovaris, Marco; Johnson, Kenneth P; Miller, Aaron; Wolinsky, Jerry S; Ladkani, David; Shifroni, Galia; Comi, Giancarlo; Filippi, Massimo // Multiple Sclerosis (13524585);Aug2003, Vol. 9 Issue 4, p349 

    Three randomized, double-blind, placebo-controlled trials have shown that glatiramer acetate (GA) is effective in reducing relapse rate in patients with relapsing-remitting (RR) multiple sclerosis (MS). Using raw data pooled from 540 patients, we performed a meta-analysis of these three trials,...

  • BIOMS REPORTS ON PHASE II DIRUCOTIDE FOR MULTIPLE SCLEROSIS.  // Worldwide Biotech;Mar2009, Vol. 21 Issue 3, p5 

    This article reports on the results from MINDSET-01, an exploratory phase II clinical trial evaluating dirucotide in patients with relapsing-remitting multiple sclerosis (MS), released by BioMS Medical Corp. The results of the study showed that dirucotide did not meet its primary endpoint,...

  • Enhanced magnetic resonance imaging in multiple sclerosis. Filippi, M. // Multiple Sclerosis (13524585);Oct2000, Vol. 6 Issue 5, p320 

    Gadolinium-enhanced magnetic resonance imaging (MRI) is very sensitive in the detection of active lesions of multiple sclerosis (MS) and has become a valuable tool to monitor the evolution of the disease either natural or modified by treatment. In the past few years, several studies, on the one...

  • Estimating cerebral atrophy in multiple sclerosis patients from various MR pulse sequences. Leigh, R; Ostuni, J; Pham, D; Goldszal, A; Lewis, BK; Howard, T; Richert, N; McFarland, H; Frank, JA // Multiple Sclerosis (13524585);Oct2002, Vol. 8 Issue 5, p420 

    Purpose: The purpose of this study was to determine how measures reflecting cerebral atrophy (CA) are influenced by pulse sequence (PS) and segmentation algorithm (SA) used in multiple sclerosis (MS) patients and healthy control (HC)s. Methods: Magnetic resonance imaging (MRI) scans from 10...

  • The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders. Durelli, L.; Barbero, P.; Bergui, M.; Versino, E.; Bassano, M.; Verdun, E.; Ferrero, B.; Rivoiro, C.; Ferrero, C.; Picco, E.; Ripellino, P.; Viglietti, D.; Giuliani, G.; Montanari, E.; Clerico, M. // Journal of Neurology;Sep2008, Vol. 255 Issue 9, p1315 

    We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNβ-1b) 375 μg (subcutaneously [sc] every other day [eod]) in relapsing-remitting multiple sclerosis (RRMS) patients with a suboptimal response to IFNβ-1b 250 μg, i.e., with MRI activity or relapses. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics